BioStock: Coegin Pharma brings new vision for cancer treatment

The Nordic biotech Coegin Pharma is responding to calls for new cancer therapeutics by offering a novel approach to cancer treatment through the inhibition of a unique and well- validated target, the cPLA2α enzyme. BioStock got in touch with CEO Tore Duvold to learn more about the company and its strategy for bringing new treatments to cancer patients.

Read the full interview with Coegin Pharma's CEO Tore Duvold at biostock.se:

https://www.biostock.se/en/coegin-pharma-brings-new-vision-for-cancer-treatment/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/